Introduction {#sec1-1}
============

Cardio-vascular disease (CVD) is the world\'s leading killer, accounting for 16.7 million or 29.2% of the total global deaths in 2003. While deaths from heart attacks have declined more than 50% since the 1960s in many industrialized countries, 80% of the global CVD related deaths now occur in low and middle-income nations, which cover most countries in Asia. In India, in the past five decades, the rate of coronary disease among urban populations has risen from 4 to 11%.\[[@CIT1]\]

Dyslipidemia (elevated total cholesterol and Low-density Lipoprotein (LDL), and depressed High-density Lipoprotein (HDL) levels are independent risk factors. Statins (HMG-CoA reductase), fibrates and resins are known dyslipidemic drugs, which act by increasing or decreasing lipoprotein (Lp) or its components levels. Many trials have been conducted to show their effectiveness in treating Coronary Artery Diseases (CAD). But very few have shown statistically significant results.

Thus, many meta-analyses have been done to verify the findings of trials involving various dyslipidemic drugs. However, most of these studies include trials of statins only; if the studies included other dyslipidemic drugs also, dietary and other kinds of interventions were also compared, along with the dyslipidemic drugs. Meta-analyses including all the dyslipidemic drug trials only are very few.

The effect of these drugs on all-cause mortality is still unclear.\[[@CIT2]--[@CIT4]\] Thus, this meta-analysis was done to evaluate the effectiveness of dyslipidemic drugs on CAD mortality, CVD mortality or all-cause mortality.

Materials and Methods {#sec1-2}
=====================

Eligibility Criteria {#sec2-1}
--------------------

Two authors separately reviewed the abstracts produced by the literature search to identify studies that are randomized placebo-controlled trials evaluating the effectiveness of any dyslipidemic drug and reporting one of the following clinical endpoints: CAD mortality, CVD mortality or all-cause mortality. The follow up period should have been greater than or equal to one year.

The most frequent reasons for study exclusion were study duration being less than one year, trial being nonrandomized or non placebo-controlled, two or more drugs being compared to a single placebo in the same study or clinical endpoints not being reported. Studies in which eligibility criteria included a particular lifestyle disease, e.g.: hypertension\[[@CIT5]\] or diabetes were excluded. Studies published in languages other than English and abstract form only were also excluded.

Study Identification {#sec2-2}
--------------------

Strategies to identify studies included an electronic search of bibliographic databases (Clinical Trials, Cochrane Reviews, PubMed and Science Direct), electronic as well as manual search of medical journals (American Journal of Cardiology, Annals of Internal Medicine, Archives of Internal Medicine, British Medical Journal, Circulation, European Heart Journal, Lancet, The Journal of the American Medical Association and The New England Journal of Medicine), consultation with the experts, review of reference lists from eligible trials and use of the "See Related Articles" feature for key publications in PubMed (March 2006).

This search resulted in the identification of 20 eligible studies, which are listed along with their characteristics in [Table 1](#T0001){ref-type="table"}. However, due to increase in heterogeneity (funnel plot), one study (ACAPS) was excluded from the final results, even though it fulfilled the inclusion/exclusion criteria. Thus, the results summarize meta-analysis of 19 studies.

###### 

Characteristics of the trials selected in this article

  *Study characteristics*                   *Drug used*      *Year of publication*   *Mean follow up duration (years)*        *Number of subjects (Intervention/Control)*   *Mean age (years)*                     *Percentage of male subjects*
  ----------------------------------------- ---------------- ----------------------- ---------------------------------------- --------------------------------------------- -------------------------------------- -------------------------------
  WOSCOP                                    Pravastatin      1995                    4.9[\*](#T000F1){ref-type="table-fn"}    3302/3293                                     55                                     100
  VA-HIT                                    Gemfibrozil      1999                    5.1                                      1264/1267                                     64                                     100
  LIPID                                     Pravastatin      1998                    6.1                                      4512/4501                                     62                                     83
  CARE                                      Pravastatin      1996                    5                                        2081/2078                                     59                                     86
  AFCAPS/TexCAPS                            Lovastatin       1998                    5.2 [\*](#T000F1){ref-type="table-fn"}   3304/3301                                     58                                     57.5
  MARS                                      Lovastatin       1993                    2.2                                      134/136                                       58[\*](#T000F1){ref-type="table-fn"}   91
  PROSPER                                   Pravastatin      2002                    3.2 [\*](#T000F1){ref-type="table-fn"}   2891/2913                                     75.3                                   48.3
  NEWCASTLE                                 Clofibrate       1971                    3.7                                      244/253                                       52.3                                   80.5
  FLORIDA                                   Fluvastatin      2002                    1                                        265/275                                       60.5                                   83
  PLAC-I                                    Pravastatin      1995                    3                                        206/202                                       57                                     37.9
  PLAC-II                                   Pravastatin      1995                    3                                        75/76                                         63                                     \-
  4S                                        Simvastatin      1994                    5.4                                      2221/2223                                     59                                     81.5
  MAAS                                      Simvastatin      1994                    4                                        193/198                                       30-67                                  \-
  CCAIT                                     Lovastatin       1995                    2                                        165/166                                       54.9                                   81
  ACAPS[\#](#T000F3){ref-type="table-fn"}   Lovastatin       1994                    2.8                                      460/459                                       61.7                                   51.5
  KAPS                                      Pravastatin      1995                    3                                        224/223                                       57                                     100
  REGRESS                                   Provastatin      1995                    2                                        450/435                                       56.2                                   100
  HPS                                       Simvastatin      2002                    5                                        10269/10267                                   \-                                     75.25
  LIPS                                      Fluvastatin      2002                    3.9[†](#T000F2){ref-type="table-fn"}     844/833                                       60                                     83.8
  CIS                                       Cholestyramine   1984                    5[\*](#T000F1){ref-type="table-fn"}      59/57                                         46.1                                   81

WOSCOP = West of Scotland Coronary Prevention Study;\[[@CIT6]\] VA-HIT=Veterans Affairs High-Density Lipoprotein Intervention Trial Study;\[[@CIT7]\] LIPID=Long-Term Intervention with Pravastatin in Ischemic Disease;\[[@CIT8]\] CARE=Cholesterol and Recurrent Events;\[[@CIT9]\] AFCAPS/TexCAPS=Air Force/Texas Coronary Prevention Study;\[[@CIT10]\] MARS=Monitored Atherosclerosis Regression Study;\[[@CIT11]\] PROSPER=Prospective Study of Pravastatin in the Elderly at Risk;\[[@CIT12]\] NEWCASTLE=Trial of Clofibrate in IHD;\[[@CIT13]\] FLORIDA=Fluvastatin on Ischemia;\[[@CIT14]\] PLAC-I=Pravastatin in Reduction of Atherosclerosis;\[[@CIT15]\] PLAC-II=Pravastatin Limitation of Atherosclerosis in the Coronary Arteries;\[[@CIT16]\] 4S=Scandinavian Simvastatin Survival Study;\[[@CIT17]\] MAAS=Simvastatin Multicentre Anti-Atheroma Study;\[[@CIT18]\] CCAIT=Canadian Coronary Atherosclerosis Intervention Trial;\[[@CIT19]\] ACAPS=Asymptomatic Carotid Artery Progression Study;\[[@CIT20]\] KAPS=Kuopio Atherosclerosis Prevention Study;\[[@CIT21]\] REGRESS=Regression Growth Evaluation Statin Study;\[[@CIT22]\] HPS=Heart Protection Study;\[[@CIT23]\] LIPS=Lescol Intervention Prevention Study;\[[@CIT24]\] CIS=Coronary Intervention Study.\[[@CIT25]\]

Average

Median

This study was dropped from the meta-analysis due to an increase in heterogeneity, even though it fulfilled the inclusion/exclusion criteria.

Data Collection {#sec2-3}
---------------

Full articles have been reviewed for eligibility. For articles meeting the inclusion criteria, relevant data was extracted and entered in the evidence table.

Statistical Analysis {#sec2-4}
--------------------

Meta-analysis was performed using the Mantel-Haenszel method for fixed effect model and Der-Simonian and the Laird method for random effect model. Graphs of the outcomes for included trials were examined visually and by using the Chi-square test to identify heterogeneity in the outcome variables across different studies. Because the results of our meta-analysis did not vary depending on whether the fixed or random effect model was used, random effect results are presented. The results are displayed as summary odds ratio (OR), relative risk (RR) and 95% confidence interval (CI) of OR and RR for CAD mortality, CVD mortality and all cause mortality. I^2^ value is also calculated. An I^2^ value represents the percentage of the total variation across trials, which is due to heterogeneity rather than chance, and is considered thus: I^2^ value \<25% is low and \>75% is high. All analyses is done using RevMan 4.2.8 (Cochrane Collaboration).

Results {#sec1-3}
=======

Figures [1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"} show the effect of treatment with dyslipidemic drugs on CAD mortality, CVD mortality and all-cause mortality. The point estimate and 95% [CI]{.ul} of OR and RR are reported. For all studies, combined patients who received treatment had a statistically significant advantage for all-cause mortality, along with CAD mortality and CVD mortality. Treatment reduced the relative risk of CHD mortality by 23% (summary relative risk is 0.77, 0.71 to 0.82), compared with placebo. For CVD mortality and all-cause mortality, reduction was by 19% (summary relative risk is 0.81, 0.76 to 0.86) and 14% (summary relative risk is 0.86, 0.81 to 0.92) respectively. The corresponding summary OR for CHD was 0.75 (95% CI: 0.70 to 0.81); for CVD the summary OR was 0.79 (95% CI: 0.74 to 0.84) and that for all- cause mortality was 0.84 (95% CI: 0.79 to 0.89) showing a reduction of 25, 21 and 16%, respectively. In each of these analysis, the results of Chi-square test for heterogeneity are not significant (*P*\>0.10) and the value of I^2^ (I^2^\<25%) suggests a fairly low amount of inconsistency across the trials included.

![Effect of dyslipidemic drugs (compared with placebo) on odds of a) CAD mortality; b) CVD mortality and c) all-cause mortality. For References, compare the patient numbers in both arms in [Table 1](#T0001){ref-type="table"}. The treatment and control columns present the number of deaths by the total number of randomized patients in that arm. The weight represents the relative weight given to the study. The final column gives the point estimate of odds ratio and its 95% confidence interval.](IJPharm-41-4-g001){#F0001}

![Risk of a) CHD mortality, b) CVD mortality and c) all-cause mortality, in the treatment group, compared to that in placebo. For References, compare the patient numbers in both arms in [Table 1](#T0001){ref-type="table"}. The treatment and control columns present the number of deaths by the total number of randomized patients in that arm. The weight represents the relative weight given to the study. The final column gives the point estimate of relative risk and its 95% confidence interval.](IJPharm-41-4-g002){#F0002}

Discussion {#sec1-4}
==========

This meta-analysis shows that lipid lowering drugs reduce the relative odds of CHD mortality, CVD mortality and all-cause mortality by about 15-25%. The population in these trials includes men, women, elderly people, hypercholesterolemic and patients with normal cholesterol levels.

The conclusions drawn in this meta-analysis are different from that of Pignone *et al.*,\[[@CIT4]\] who found that the effect of statins on all-cause mortality is insignificant. The differences are possibly because 1) Pignone *et al*, limited their analysis to the statin trials only. 2) They included only primary prevention trials. Unlike their study, in this meta-analysis, studies of fibrates and resins have been also included. Apart from this, primary, secondary as well as mixed type trials have been included in this meta-analysis. But these conclusions are similar to that drawn by Ross *et al.*,\[[@CIT26]\] who found that statins are effective in reducing CVD mortality, along with all-cause mortality (OR = 0.76, 0.67 to 0.86).

The differences are due to the exclusion of studies in which a second drug was added if the targeted levels of cholesterol were not achieved, in our meta-analysis.

Generalization of these findings to other populations -- such as Asians -- is difficult, as trials selected for the analysis do not adequately represent this population. Generally, the population that participated was of European or American descent.

The strength of this meta-analysis is that it is based on more than 50,000 randomized patients. However, the short comings of this analysis are: 1) it was not based on individual data but available data from the literature; 2) some of the articles could not be included as they were unavailable; 3) absolute risk was not calculated.

Future research can be done to know the effectiveness of dyslipidemic drugs on people of non European origin. Further research can be done to calculate absolute values to strengthen the findings in this analysis.
